Analyst Ratings February 13, 2026

Goldman Sachs Moves Upstart to Neutral, Sets $35 Price Objective

Firm cites market recognition of margin and take-rate pressures after stock underperformed; Upstart posts mixed Q4 2025 results and faces a separate downgrade

By Marcus Reed UPST
Goldman Sachs Moves Upstart to Neutral, Sets $35 Price Objective
UPST

Goldman Sachs shifted its rating on Upstart Holdings Inc. (UPST) from Sell to Neutral and assigned a $35.00 price target, saying that prior concerns about margin and take-rate compression are now more broadly reflected in the market following the stock's underperformance. Upstart reported mixed fourth-quarter 2025 results, with earnings per share missing estimates while revenue topped forecasts. Separately, Citizens cut its rating to Market Underperform and set a $20.00 target based on valuation concerns tied to clearer medium-term guidance.

Key Points

  • Goldman Sachs upgraded Upstart from Sell to Neutral and set a $35.00 price target, citing improved market recognition of risks and stock underperformance.
  • Upstart reported Q4 2025 EPS of $0.17, missing the $0.46 estimate by 63.04%, while revenue of $296 million exceeded the $288.45 million forecast by 2.64%.
  • Citizens downgraded Upstart from Market Perform to Market Underperform and set a $20.00 target, pointing to valuation concerns after clearer medium-term guidance.

Goldman Sachs on Friday revised its recommendation on Upstart Holdings Inc. (NASDAQ: UPST), raising the rating from Sell to Neutral and establishing a price target of $35.00. The firm explained that the shares have weakened enough that the balance of upside and downside risk appears more even for investors.

The bank’s earlier Sell view was driven by worries that new product introductions could lead to compression in take rates and contribution margins, risks Goldman believed the market had not fully priced in. Goldman also cited expectations for peak cycle dynamics in consumer lending around the summer of 2025 as part of the rationale behind its prior cautious stance.

Following those concerns, Upstart recorded somewhat slower-than-expected volumes during the second half of 2025 and issued guidance reflecting the take-rate and contribution margin compression that Goldman had warned about. Goldman Sachs said these developments are now better understood by market participants, and combined with the stock’s relative underperformance, the firm adjusted its recommendation to Neutral.

In corporate results, Upstart released fourth-quarter 2025 financials that produced mixed signals. Reported earnings per share were $0.17, below the consensus estimate of $0.46, representing a 63.04% negative surprise. Revenue, however, came in at $296 million, beating the forecasted $288.45 million for a 2.64% upside surprise.

Adding to the momentum of analyst activity, Citizens moved in the opposite direction on Upstart, lowering its rating from Market Perform to Market Underperform and assigning a $20.00 price target. Citizens cited valuation considerations after gaining what it described as greater clarity on Upstart’s earnings trajectory under the company’s new medium-term guidance.

Taken together, the analyst actions and the company’s latest quarter highlight a period of recalibration for Upstart, with market participants and research shops reassessing the implications of weaker volume trends and anticipated margin pressures for the firm’s near-term performance.


Disclosure:

Risks

  • Take-rate and contribution margin compression tied to new products could continue to pressure profitability - impacting the fintech and consumer lending sectors.
  • Slower-than-expected volumes in consumer lending represent uncertainty for Upstart’s revenue and earnings trajectory - affecting financials and credit markets.

More from Analyst Ratings

HSBC Lowers Synopsys Rating to Hold, Flags 2026 as Transition Year Feb 21, 2026 DA Davidson Cuts Uber Price Target Citing Elevated Investment; Buy Rating Intact Feb 20, 2026 Freedom Capital Markets Raises Freeport-McMoRan to Buy, Cites Copper Supply Tightness Feb 20, 2026 BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026 Truist Lifts Tandem Diabetes Price Target as Company Shifts Toward Pharmacy Model Feb 20, 2026